The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Open accessAbstract
Anticancer drugs resistance is a complex process that arises from altering in the drug targets. Advances in the DNA microarray, proteomics technology and the development of targeted therapies provide the new strategies to overcome the drug resistance. Although a design of the new chemotherapy agents is growing quickly, effective chemotherapy agent has not been discovered against the advanced stage of cancer (such as invasion and metastasis). The cancer cell resistance against the anticancer agents can be due to many factors such as the individual's genetic differences, especially in tumoral somatic cells. Also, the cancer drug resistance is acquired, the drug resistance can be occurred by different mechanisms, including multi-drug resistance, cell death inhibiting (apoptosis suppression), altering in the drug metabolism, epigenetic and drug targets, enhancing DNA repair and gene amplification. In this review, we outlined the mechanisms of cancer drug resistance and in following, the treatment failures by common chemotherapy agents in the different type of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Li, H., Zhang, P., Sun, X., Sun, Y., Shi, C., Liu, H., & Liu, X. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3144 · Cited by 58
RetractedCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
ABC Transporters: From Microorganisms to Man
Higgins, C. F. (1992) · Annual Review of Cell Biology · doi:10.1146/annurev.cb.08.110192.000435 · Cited by 3,985
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Chen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
A family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
Gupta, P. B., Fillmore, C. M., Jiang, G., Shapira, S. D., Tao, K., Kuperwasser, C., & Lander, E. S. (2011) · Cell · doi:10.1016/j.cell.2011.07.026 · Cited by 1,475
The role of glutathione-S-transferase in anti-cancer drug resistance
Townsend, D. M., & Tew, K. D. (2003) · Oncogene · doi:10.1038/sj.onc.1206940 · Cited by 1,353
Inaba, H., Greaves, M., & Mullighan, C. G. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62187-4 · Cited by 1,074
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration
Pui, C.-H., Yang, J. J., Hunger, S. P., Pieters, R., Schrappe, M., Biondi, A., Vora, A., Baruchel, A., Silverman, L. B., Schmiegelow, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1636 · Cited by 1,007
Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
Arora, V. K., Schenkein, E., Murali, R., Subudhi, S. K., Wongvipat, J., Balbas, M. D., Shah, N., Cai, L., Efstathiou, E., Logothetis, C., et al. (2013) · Cell · doi:10.1016/j.cell.2013.11.012 · Cited by 986
Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer
Kreso, A., O'Brien, C. A., van Galen, P., Gan, O. I., Notta, F., Brown, A. M. K., Ng, K., Ma, J., Wienholds, E., Dunant, C., et al. (2013) · Science · doi:10.1126/science.1227670 · Cited by 744
Mutations in the MDR 3 gene cause progressive familial intrahepatic cholestasis
de Vree, J. M. L., Jacquemin, E., Sturm, E., Cresteil, D., Bosma, P. J., Aten, J., Deleuze, J.-F., Desrochers, M., Burdelski, M., Bernard, O., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.282 · Cited by 735
Simon, J. A., & Kingston, R. E. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.02.013 · Cited by 733
GOODMAN, L. S. (1946) · Journal of the American Medical Association · doi:10.1001/jama.1946.02870380008004 · Cited by 700
Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal Mutant EGFR DNA
Nathanson, D. A., Gini, B., Mottahedeh, J., Visnyei, K., Koga, T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., et al. (2014) · Science · doi:10.1126/science.1241328 · Cited by 695
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
Croop, J. M., Raymond, M., Haber, D., Devault, A., Arceci, R. J., Gros, P., & Housman, D. E. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1346 · Cited by 463
Goldenberg, M. M. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88288-0 · Cited by 453
Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia
Steelman, L. S., Abrams, S. L., Whelan, J., Bertrand, F. E., Ludwig, D. E., Bäsecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., et al. (2008) · Leukemia · doi:10.1038/leu.2008.26 · Cited by 385
Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines
Hollestelle, A., Elstrodt, F., Nagel, J. H. A., Kallemeijn, W. W., & Schutte, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0263 · Cited by 320
Immunotoxins for targeted cancer therapy
Kreitman, R. J. (2006) · The AAPS Journal · doi:10.1208/aapsj080363 · Cited by 307
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Amplification of the metallothionein-I gene in cadmium-resistant mouse cells.
Beach, L. R., & Palmiter, R. D. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2110 · Cited by 296
Grandage, V. L., Gale, R. E., Linch, D. C., & Khwaja, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403653 · Cited by 281
Cumming, R. C., Lightfoot, J., Beard, K., Youssoufian, H., O'Brien, P. J., & Buchwald, M. (2001) · Nature Medicine · doi:10.1038/89937 · Cited by 245
Clinical Implications of the Cancer Genome
MacConaill, L. E., & Garraway, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4944 · Cited by 229
Wang, Z., Wang, N., Liu, P., Chen, Q., Situ, H., Xie, T., Zhang, J., Peng, C., Lin, Y., & Chen, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2192 · Cited by 224
(1949) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1949.tb68027.x · Cited by 215
AKT/PKB signaling mechanisms in cancer and chemoresistance
Kim, D. (2005) · Frontiers in Bioscience · doi:10.2741/1592 · Cited by 204
Hazlehurst, L. A., Landowski, T. H., & Dalton, W. S. (2003) · Oncogene · doi:10.1038/sj.onc.1206943 · Cited by 203
Genetic and epigenetic aspects of breast cancer progression and therapy.
Byler, S., Goldgar, S., Heerboth, S. A., Leary, M., Housman, G., Moulton, K. L., & Sarkar, S. (2014) · PubMed · Cited by 203
miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1
Shang, Y., Zhang, Z., Liu, Z., Feng, B., Ren, G., Li, K., Zhou, L., Sun, Y., Li, M., Zhou, J., et al. (2014) · Oncogene · doi:10.1038/onc.2013.297 · Cited by 188
RNA Interference and its Role in Cancer Therapy
Mansoori, B., Shotorbani, S. S., & Baradaran, B. (2014) · PubMed · doi:10.5681/apb.2014.046 · Cited by 180
Self-citationTumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
Michael, M., & Doherty, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.120 · Cited by 177
Sampath, D., Cortes, J., Estrov, Z., Du, M., Shi, Z., Andreeff, M., Gandhi, V., & Plunkett, W. (2005) · Blood · doi:10.1182/blood-2005-08-3351 · Cited by 160
Mattos‐Arruda, L. D., Bottai, G., Nuciforo, P. G., Tommaso, L. D., Giovannetti, E., Peg, V., Losurdo, A., Pérez-García, J. M., Masci, G., Corsi, F., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5495 · Cited by 159
Tumor microenvironment and drug resistance in hematologic malignancies
Li, Z., & Dalton, W. S. (2006) · Blood Reviews · doi:10.1016/j.blre.2005.08.003 · Cited by 158
Benner, S. E., Wahl, G. M., & Hoff, D. D. V. (1991) · Anti-Cancer Drugs · doi:10.1097/00001813-199102000-00002 · Cited by 139
de Toni, F., Racaud‐Sultan, C., Chicanne, G., Mas, V. M., Cariven, C., Briand‐Mésange, F., Salles, J., Demur, C., Allouche, M., Payrastre, B., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1209346 · Cited by 134
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
Luo, J.-M., Yoshida, H., Komura, S., Ohishi, N., Pan, L., Shigeno, K., Hanamura, I., Miura, K., Iida, S., Ueda, R., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402725 · Cited by 127
Gullà, A., Martino, M. T. D., Cantafio, M. E. G., Morelli, E., Amodio, N., Botta, C., Pitari, M. R., Lio, S. G., Britti, D., Stamato, M. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0489 · Cited by 124
Wu, Q., Yang, Z., Xia, L., Nie, Y., Wu, K., Shi, Y., & Fan, D. (2014) · Oncotarget · doi:10.18632/oncotarget.2594 · Cited by 124
Gene amplification: mechanisms and involvement in cancer
Matsui, A., Ihara, T., Suda, H., Mikami, H., & Semba, K. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0026 · Cited by 115
Zhu, X., Li, Y., Xie, C., Yin, X., Liu, Y., Cao, Y., Fang, Y., Lin, X., Xu, Y., Xu, W., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28774 · Cited by 114
The evolutionary dynamics of cancer prevention
Gatenby, R. A., Gillies, R. J., & Brown, J. S. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2892 · Cited by 105
To, K. K. W., Leung, W. W., & Ng, S. S. M. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.09.011 · Cited by 99
Munoz, J. L., Rodriguez‐Cruz, V., Ramkissoon, S. H., Ligon, K. L., Greco, S. J., & Rameshwar, P. (2015) · Oncotarget · doi:10.18632/oncotarget.2778 · Cited by 98
Hiraki, M., Nishimura, J., Takahashi, H., Wu, X., Takahashi, Y., Miyo, M., Nishida, N., Uemura, M., Hata, T., Takemasa, I., et al. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.5 · Cited by 97
Barinaga, M. (1997) · Science · doi:10.1126/science.278.5340.1036 · Cited by 95
Longo-Sorbello, G. S. A., & Bertino, J. R. (2001) · PubMed · Cited by 92
The tumor microenvironment: focus on myeloma
Dalton, W. J. (2003) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(03)00077-x · Cited by 91
Sui, H. X., Cai, G.-X., Pan, S.-F., Deng, W.-L., Wang, Y., Chen, Z., Cai, S.-J., Zhu, H.-R., & Li, Q. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0167 · Cited by 89
van Jaarsveld, M. T. M., van Kuijk, P. F., Boersma, A. W. M., Helleman, J., van IJcken, W. F. J., Mathijssen, R. H. J., Pothof, J., Berns, E. M. J. J., Verweij, J., & Wiemer, E. A. C. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0464-4 · Cited by 86
JAK2 the future: therapeutic strategies for JAK-dependent malignancies
LaFave, L. M., & Levine, R. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.08.005 · Cited by 84
Jones, D. M., Kamel‐Reid, S., Bahler, D. W., Dong, H. Y., Elenitoba‐Johnson, K. S. J., Press, R. D., Quigley, N. B., Rothberg, P. G., Sabath, D., Viswanatha, D. S., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080095 · Cited by 83
Childhood leukemia and residential proximity to industrial and urban sites
García‐Pérez, J., López‐Abente, G., Gómez‐Barroso, D., Morales-Piga, A. A., Romaguera, E. P., Tamayo, I., Fernández‐Navarro, P., & Ramis, R. (2015) · Environmental Research · doi:10.1016/j.envres.2015.05.014 · Cited by 76
Manolitsas, T., Englefield, P., Eccles, D., & Campbell, I. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.238 · Cited by 74
miR‐7 modulates chemoresistance of small cell lung cancer by repressing MRP 1/ ABCC 1
Liu, H., Wu, X., Huang, J., Peng, J., & Guo, L. (2015) · International Journal of Experimental Pathology · doi:10.1111/iep.12131 · Cited by 74
Micro-RNAs: The new potential biomarkers in cancer diagnosis, prognosis and cancer therapy.
Mansoori, B., Mohammadi, A., Shirjang, S., & Baradaran, B. (2015) · PubMed · Cited by 71
Self-citationmiR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1
Zhang, Y., Qu, X., Li, C., Fan, Y., Che, X., Wang, X., Cai, Y., Hu, X., & Liu, Y. (2014) · Tumor Biology · doi:10.1007/s13277-014-2835-7 · Cited by 70
Fang, Y., Xu, C., & Fu, Y. (2015) · Journal of Biological Research - Thessaloniki · doi:10.1186/s40709-015-0035-2 · Cited by 61
Li, J., Luo, N., Zhong, M., Xiao, Z., Wang, J., Yao, X., Peng, Y., & Cao, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4017-7 · Cited by 59
Lü, L., Fang, J., Zhao, H., & Ma, X. (2015) · Biotechnology Letters · doi:10.1007/s10529-015-1941-y · Cited by 57
Dimude, J. U., Stockum, A., Midgley-Smith, S. L., Upton, A. L., Foster, H. A., Khan, A., Saunders, N. J. S. G., Retkutė, R., & Rudolph, C. J. (2015) · mBio · doi:10.1128/mbio.01294-15 · Cited by 56
Lothstein, L., Hsu, S. I., Horwitz, S. B., et al. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)71586-x · Cited by 44
Mechanisms of tumour resistance against chemotherapeutic agents in veterinary oncology
Klopfleisch, R., Kohn, B., & Gruber, A. D. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.06.015 · Cited by 43
Settleman, J. (2016) · Nature · doi:10.1038/nature16863 · Cited by 43
Montazami, N., Andish, M. K., Majidi, J., Yousefi, M., Yousefi, B., Mohamadnejad, L., Shanebandi, D., Estiar, M. A., Khaze, V., Mansoori, B., et al. (2015) · PubMed · Cited by 39
Self-citationSmith, C. E., Bowen, N., Graham, W. J., Goellner, E. M., Srivatsan, A., & Kolodner, R. D. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.662189 · Cited by 35
Nabholtz, J., & Slamon, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90187-3 · Cited by 31
Feng, R., & Dong, L. (2015) · Europe PMC (PubMed Central) · Cited by 29
Kachalaki, S., Baradaran, B., Majidi, J., Yousefi, M., Shanehbandi, D., Mohammadinejad, S., & Mansoori, B. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.08.032 · Cited by 29
Self-citationStudy on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells
Shen, X., Guo, Y., Qi, J., Shi, W., Wu, X., Ni, H., & Ju, S. (2015) · Pathology & Oncology Research · doi:10.1007/s12253-015-0035-4 · Cited by 29
The Diverse Effects of Complex Chromosome Rearrangements and Chromothripsis in Cancer Development
de Pagter, M. S., & Kloosterman, W. P. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_8 · Cited by 24
Classical and Targeted Anticancer Drugs: An Appraisal of Mechanisms of Multidrug Resistance
Baguley, B. C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3347-1_2 · Cited by 17
Cited by
Mechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Long Non-Coding RNA in the Pathogenesis of Cancers
Chi, Y., Wang, D., Wang, J., Yu, W., & Yang, J. (2019) · Cells · doi:10.3390/cells8091015 · Cited by 791
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Metadata
- Authors
- Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B.
- Venue
- Advanced Pharmaceutical Bulletin
- Publisher
- Maad Rayan Publishing Company
- Published
- 2017-09-25
- Volume
- 7
- Issue
- 3
- Pages
- 339-348
- ISSN
- 2228-5881 (ISSN-L)
- 2251-7308
- OpenAlex
- W2769426045
- Cited by
- 1,883
- References
- 83
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.